Mizuho restated their hold rating on shares of Incyte (NASDAQ:INCY) in a research report sent to investors on Thursday, AnalystRatings.com reports. They currently have a $79.00 price target on the biopharmaceutical company’s stock.
Several other research analysts also recently commented on INCY. JPMorgan Chase & Co. reiterated a buy rating on shares of Incyte in a research note on Tuesday, January 14th. JMP Securities reiterated an outperform rating and set a $121.00 target price on shares of Incyte in a research note on Tuesday, January 14th. Guggenheim downgraded Incyte from a buy rating to a neutral rating in a research note on Thursday, January 2nd. Evercore ISI reiterated a buy rating and set a $92.00 target price on shares of Incyte in a research note on Monday, January 27th. Finally, Credit Suisse Group reduced their target price on Incyte from $90.00 to $86.00 and set a neutral rating for the company in a research note on Friday, January 3rd. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Incyte has an average rating of Hold and an average target price of $91.45.
Shares of NASDAQ INCY traded up $0.40 during midday trading on Thursday, hitting $78.45. 1,370,174 shares of the company’s stock were exchanged, compared to its average volume of 1,612,612. The company has a quick ratio of 5.01, a current ratio of 5.02 and a debt-to-equity ratio of 0.02. Incyte has a 12 month low of $71.84 and a 12 month high of $96.79. The company’s 50 day moving average price is $78.56 and its 200 day moving average price is $82.10. The firm has a market capitalization of $16.81 billion, a PE ratio of 42.18, a price-to-earnings-growth ratio of 0.84 and a beta of 1.06.
In related news, EVP Yao Wenqing sold 3,165 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $95.00, for a total value of $300,675.00. Following the completion of the sale, the executive vice president now directly owns 98,473 shares in the company, valued at approximately $9,354,935. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Paul Trower sold 15,000 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $93.76, for a total value of $1,406,400.00. Insiders sold a total of 42,142 shares of company stock valued at $3,931,005 over the last 90 days. 17.10% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in INCY. Savior LLC acquired a new position in Incyte in the 4th quarter valued at $27,000. Huntington National Bank acquired a new position in Incyte in the 4th quarter valued at $28,000. Advisory Alpha LLC raised its holdings in Incyte by 2,122.2% in the 4th quarter. Advisory Alpha LLC now owns 400 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 382 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its holdings in Incyte by 617.7% in the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 445 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 383 shares in the last quarter. Finally, Parallel Advisors LLC raised its holdings in Incyte by 134.0% in the 4th quarter. Parallel Advisors LLC now owns 468 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 268 shares in the last quarter. Institutional investors and hedge funds own 91.06% of the company’s stock.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.
Recommended Story: What member countries make up the G-20?
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.